Tech Company Financing Transactions
Mosanna Therapeutics Funding Round
Forty51 Ventures, High-Tech Gründerfonds and Supermoon Capital invested in a Seed funding round for Mosanna Therapeutics. The financing round was announced by the company on 4/12/2023.
Transaction Overview
Company Name
Announced On
4/12/2023
Transaction Type
Venture Equity
Amount
Unknown
Round
Seed
Proceeds Purpose
The company intends to use the funds for manufacturing and regulatory activities in preparation for a multi-study clinical development program.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Grellingerstrasse 91
Basel, 4052
CH
Basel, 4052
CH
Phone
Undisclosed
Website
Email Address
Overview
Mosanna is a Swiss Biotech company based in Basel with a commitment to improving patient outcomes and quality of life in high unmet need diseases, applying a precision medicine approach. We carefully select innovative medicines for further development using the best contract research organisations in the specific specialised field. Our first goal is to bring an effective and well tolerated medicinal nasal spray to Metabolic Obstructive Sleep Apnea patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Bernardus Machielse
Chief Executive Officer
Jonathan Talbot
Browse more venture capital transactions:
Prev: 4/12/2023: Zeely venture capital transaction
Next: 4/12/2023: Hometree venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to document every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs